The legal battle over mifepristone, a drug used in approximately 60% of abortions across the United States, has made its way back to the Supreme Court. The case, Danco Laboratories v. Louisiana, revolves around the rulings of the U.S. Court of Appeals for the 5th Circuit which reinstated a mandate that mifepristone must be dispensed in person, challenging the Food and Drug Administration’s (FDA) guidelines that allowed more flexible distribution.
In 2024, the Supreme Court had previously ruled in FDA v. Alliance for Hippocratic Medicine that anti-abortion medical groups lacked standing to contest the FDA’s approval processes and regulations concerning mifepristone. The current case was initiated by Louisiana, which argues that the FDA’s rules permitting the mailing of mifepristone violate its state laws that generally prohibit abortions.
In response, Danco Laboratories and another manufacturer, GenBioPro, submitted an emergency application to the Supreme Court, challenging the 5th Circuit’s decision and seeking a temporary stay while the matter is considered. They cite the potential confusion and complications the ruling brings to critical medical decisions and argue that the claims of Louisiana are more attenuated than those rejected by the court two years ago.
Justice Samuel Alito, who receives emergency requests from the 5th Circuit, will initially review the application. The matters under consideration will test the Supreme Court’s previous assertion of what constitutes standing in federal court, as Louisiana’s position emphasizes a direct confrontation with federal law versus state restrictions on abortion practices following the Dobbs v. Jackson Women’s Health Organization decision.
The ongoing judicial navigation around mifepristone’s distribution and the emergent tension between federal guidelines and state restrictions highlight a contentious area in U.S. reproductive health law. For more detailed information, you can read the full text of the case proceedings on SCOTUSblog.